Granting of Patents Related to MUSCAT ASSAY
First written in FY2017. 2 of 4 entries say "Advanced", first in FY2025. Latest entry: 2026-05-27.
No other company in this theme has enough history to compare yet.
- 2026-05-27AdvancedPresentation materials on financial results
「Publication of a paper on S-cationization technology (March)」
For the MUSCAT-Assay, the company reported publication of a paper and the collection and analysis of additional data, while continuing to consider applications in cancer risk testing. - FY2025AdvancedAnnual report
「Analysis using machine learning of autoantibody measurements from healthy individuals and lung cancer patients showed that healthy individuals could be distinguished from cancer patients with extremely high accuracy.」
For the MUSCAT assay, the Company confirmed the feasibility of distinguishing healthy individuals from lung cancer patients using machine learning and is advancing practical-application research as a diagnostic agent and cancer-risk testing method. - FY2019RestatedAnnual report
「The Company is currently examining the potential of the high-sensitivity antibody detection technology "MUltiple S-CATionized antigen beads array Assay = MUSCAT ASSAY," which is being jointly researched with Okayama University and others, as a diagnostic agent for assessing the efficacy of tumor immunotherapy and other applications.」
The Company is continuing to examine the potential of MUSCAT ASSAY as a diagnostic agent for assessing the efficacy of tumor immunotherapy and other applications. - FY2017AchievedAnnual report
「Patents for the highly sensitive antibody detection technology “MUltiple S-CATionized antigen beads array Assay = MUSCAT ASSAY,” developed through joint research with Okayama University and others, were granted in the People’s Republic of China, Singapore, Taiwan and Japan during the fiscal year.」
Patents for the jointly researched MUSCAT ASSAY were granted in China, Singapore, Taiwan and Japan.